Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Linezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | SDHA | P31040 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CALML3 | P27482 | 1/20 | 1.00 |
| ▸ | F10 | P00742 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linezolid SCHEMBL30226927 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30638355 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL7992562 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL1561095 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5027 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5524444 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2222512 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2280731 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2279924 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2277149 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635307-B1 | PHARMACEUTICAL COMPOSITIONS | MELINTA SUBSIDIARY CORP (US) | 2020-07-29 | — | — | EP | claimed |
| US-9795601-B2 | Compositions and methods for cancer treatment | BIOVISTA, INC. (US) | 2017-10-24 | — | — | US | claimed |
| CN-103379917-A | Pharmaceutical composition | RIB X PHARMACEUTICALS INC | 2013-10-30 | — | — | CN | claimed |
| EP-2635307-A2 | PHARMACEUTICAL COMPOSITIONS | Rib-X Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061360-A2 | PHARMACEUTICAL COMPOSITIONS | RIB-X PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | claimed |
| US-7892574-B2 | In situ applying oxazolidinone to ear, skins | PHARMACIA & UPJOHN COMPANY, LLC (US) | 2011-02-22 | — | — | US | claimed |
| CN-1221547-C | Leiyin zorride-type II crystal | UPJOHN CO (US) | 2005-10-05 | — | — | CN | claimed |
| EP-1096934-B1 | OXAZOLIDINONES TO TREAT EYE INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1301207-B1 | COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS, CONTAINING AN OXAZOLIDINONE COMPOUND, SULBACTAM AND AND AMPICILLIN | PHARMACIA & UPJOHN CO LLC (US) | 2005-08-10 | — | — | EP | claimed |
| CN-1642543-A | Parenteral, intravenous and oral administration of oxazolidinones for the treatment of diabetic foot infections | PHARMACIA & UPJOHN (US) | 2005-07-20 | — | — | CN | claimed |
| WO-2001057035-A1 | LINEZOLID-CRYSTAL FORM II | PHARMACIA & UPJOHN COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
| CN-1305374-A | Oxazolidinones to treat eye infections | UPJOHN CO (US) | 2001-07-25 | — | — | CN | claimed |
| CN-1299281-A | Use of oxazolidinone derivatives for the treatment of psoriasis, arthritis and for reducing the toxicity of cancer chemotherapy | UPJOHN CO (US) | 2001-06-13 | — | — | CN | claimed |
| CN-1298302-A | Topical administration of oxazolidinones for transdermal delivery | UPJOHN CO (US) | 2001-06-06 | — | — | CN | claimed |
| EP-1096934-A1 | OXAZOLIDINONES TO TREAT EYE INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2001-05-09 | — | — | EP | claimed |
| EP-1032386-A1 | USE OF OXAZOLIDINONE DERIVATITIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-06 | — | — | EP | claimed |
| US-6040306-A | Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy | PHARMACIA & UPJOHN COMPANY | 2000-03-21 | — | — | US | claimed |
| WO-2000003710-A1 | OXAZOLIDINONES TO TREAT EYE INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2000-01-27 | — | — | WO | claimed |
| EP-0717738-B1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1999025344-A1 | USE OF OXAZOLIDINONE DERIVATIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-27 | — | — | WO | claimed |